Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the treatment of dementia and preparation method thereof

A composition and dementia technology, applied in the directions of drug combinations, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problems of obvious side effects, hinder the progressive process of the disease course, and narrow the treatment range, and achieve the goal of promoting nerve growth, The effect of preventing senile dementia and improving memory function in the elderly

Active Publication Date: 2014-09-17
HEILONGJIANG ZBD PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effect shown is also only a partial and temporary improvement of cognitive function, but does not hinder the progressive course of the disease course
Due to the narrow therapeutic range and obvious side effects of western medicine in the treatment of AD, many researchers have begun to focus on traditional Chinese medicine for the treatment of AD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the treatment of dementia and preparation method thereof
  • Pharmaceutical composition for the treatment of dementia and preparation method thereof
  • Pharmaceutical composition for the treatment of dementia and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 is used for the pharmaceutical composition (bilobalide and ginkgolide A) and preparation method thereof for the treatment of dementia

[0033] Get ginkgo leaf extract 100g (the weight ratio of ginkgolide A, ginkgolide B, ginkgolide C and bilobalide is 1:1:1:1), add 2000ml ethyl acetate to extract 3 times, steam under reduced pressure Dry to obtain total ginkgo lactones; dissolve total ginkgo lactones with 200ml water, pass through D101 adsorption resin for 1h, then elute with 200ml10% ethanol for 1-4 column volumes, collect eluate, and collect The eluate was evaporated to dryness under reduced pressure at 60°C and -0.09MPa to obtain crude bilobalide; heat the crude bilobalide to 50°C with 400ml of 80% ethanol, dissolve it, filter it while it is hot, and store it in a refrigerator at 4°C After 12 hours, crystals were precipitated, and vacuum-dried at 60°C to obtain 43 g of the bilobalide composition.

[0034] After testing, the total ginkgolic acid: the HPL...

Embodiment 2

[0036] Embodiment 2 is used for the treatment of dementia pharmaceutical composition (bilobalide and ginkgolide A, ginkgolide C) and preparation method thereof

[0037] Get Ginkgo biloba extract 80g (the weight ratio of ginkgolide A, ginkgolide B, ginkgolide C and bilobalide is 5:2:3:10), add 1600ml n-butanol extraction 6 times, steam under reduced pressure Dry to obtain total ginkgo lactones; dissolve total ginkgo lactones with 200ml water, pass through D101 adsorption resin, adsorption time 2h, elute 1-4 column volumes with 300ml10% ethanol, collect eluate, and collect Rotate the eluate at 55°C and -0.1MPa to dryness under reduced pressure, recover the solvent to dryness under reduced pressure to obtain the crude product of bilobalide; heat the crude product of bilobalide to 70°C with 300ml of 60% ethanol, dissolve it while hot Filtrate, refrigerate at 4°C for 24h, precipitate crystals, and dry in vacuum at 60°C to obtain 35g of bilobalide composition.

[0038] After testin...

Embodiment 3

[0040] Embodiment 3 is used for the treatment of the pharmaceutical composition of dementia (bilobalide and ginkgolide C) and preparation method thereof

[0041] Get 100g of Ginkgo biloba extract (the weight ratio of ginkgolide A, ginkgolide B, ginkgolide C and bilobalide is 1:2:3:10), add 800ml acetone to extract 3 times, evaporate to dryness under reduced pressure, The total ginkgo lactones are obtained; the total ginkgo lactones are dissolved in 200ml of water, passed through D101 adsorption resin, the adsorption time is 0.5h, and 1-4 column volumes are eluted with 200ml20% ethanol, the eluate is collected, and the collected eluate Remove the liquid at 65°C and -0.09MPa under reduced pressure and rotary evaporation to dryness, recover the solvent to dryness under reduced pressure to obtain the crude product of bilobalide; heat the crude product of bilobalide to 60°C with 400ml of 40% ethanol, dissolve and filter while hot , refrigerated at 4°C for 18h, precipitated crystals...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for the treatment of dementia and a preparation method thereof. The pharmaceutical composition comprises bilobalide and one or two or a combination of ginkgolide A and ginkgolide C. The pharmaceutical composition containing bilobalide provided by the invention has a neuroprotective effect in many aspects, including promoting nerve growth, improving the memory function of the elderly and preventing the occurrence of dementia, etc. Experiments show that the product has certain role to improve memory impairment in mice in the treatment of Alzheimer's disease.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating dementia and a preparation method thereof. Background technique [0002] Dementia includes Alzheimer's disease (AD) and cerebrovascular dementia (VD), of which Alzheimer's disease is the most common form of dementia, this neurodegenerative disease can cause memory loss, cognitive function damage, and eventually death. The clinical treatment of AD is an unsolved worldwide problem. Currently, most of the anti-dementia drugs used clinically are symptomatic treatments (mainly to improve cognitive function), such as cholinesterase inhibitors, polypeptides, nootropic drugs, Antioxidant etc. The shown effects also only partially and temporarily improve cognitive function, but do not hinder the progressive course of the disease course. Due to the narrow therapeutic range and obvious side effects of western medicine in the treatment of AD, many r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P25/28
Inventor 方同华马丽梅李振宇周广红范玉奇赵春丽
Owner HEILONGJIANG ZBD PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com